Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Domino's Pizza, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Domino's Pizza, Inc. trades at $300.3 (market cap $9.96B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DPZ | |
|---|---|---|
Market Cap | $39.89B | $9.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $485.53 |
52-Week Low | $278.09 | $282.89 |
Enterprise Value | $38.15B | $14.86B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Domino's Pizza (DPZ) trades at $299.46, down 0.47% on the day, near its 52-week low. The stock shows a bearish technical signal with support at $297 and resistance at $304. Fundamentally, revenue grew to $4.94B in 2025 with a net income margin of 11.89%, though recent quarters have seen earnings misses. The company maintains strong profitability but faces headwinds from slowing US sales growth and a CEO transition announced in June 2026.
The outlook is mixed: analyst consensus is bullish with a $380.31 price target, but near-term risks include competitive pressures and macroeconomic challenges. Long-term investors may find value at current levels given the company's market dominance and digital capabilities, though execution under new leadership and sales recovery are critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
